{"id":"NCT01635764","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa","officialTitle":"A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2016-08","completion":"2016-08","firstPosted":"2012-07-10","resultsPosted":"2017-09-05","lastUpdate":"2018-01-24"},"enrollment":508,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hidradenitis Suppurativa"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["Humira"]}],"arms":[{"label":"Adalimumab Every Week","type":"EXPERIMENTAL"}],"summary":"The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).","primaryOutcome":{"measure":"Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit","timeFrame":"Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216","effectByArm":[{"arm":"EW/EW/EW","deltaMin":34.1,"sd":null},{"arm":"EW/EOW/EW","deltaMin":39.8,"sd":null},{"arm":"EW/PBO/EW","deltaMin":34.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":508},"commonTop":["HIDRADENITIS","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE","INFLUENZA"]}}